Trial Profile
Leukemia SPORE Phase II Randomized Study of Decitabine Versus Decitabine and Carboplatin Versus Decitabine and Arsenic in Relapsed, Refractory and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2017
Price :
$35
*
At a glance
- Drugs Arsenic trioxide (Primary) ; Carboplatin (Primary) ; Decitabine (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 15 Jan 2016 New trial record
- 08 Dec 2015 Results (n=42) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.